Santen Pharmaceutical Co., Ltd. (SNPHY)
| Market Cap | 3.36B |
| Revenue (ttm) | 1.92B |
| Net Income (ttm) | 174.88M |
| Shares Out | n/a |
| EPS (ttm) | 0.49 |
| PE Ratio | 19.23 |
| Forward PE | n/a |
| Dividend | 0.25 (2.44%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 21,480 |
| Average Volume | 7,130 |
| Open | 9.65 |
| Previous Close | 10.07 |
| Day's Range | 9.65 - 9.92 |
| 52-Week Range | 8.65 - 13.00 |
| Beta | 0.20 |
| RSI | 56.97 |
| Earnings Date | May 13, 2025 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in pha... [Read more]
News
Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript
Santen Pharmaceutical Co., Ltd. (OTCPK:SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 3:30 AM ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Peter ...